Brain, Vol. 125, No. 10, 2213-2221,
October 2002
© 2002 Oxford University Press
PMP22 overexpression causes dysmyelination in mice
1 INSERM U491, Medical Genetics and Development, 2 UPRES JE 2053, Nervous and Muscular Biopathology, 3 Service de Microscopie Électronique, Faculté de Médecine de la Timone, 4 Movement, Development and Pathology Laboratory, CNRS 31, Chemin J. Aiguier, Marseille, France*These two authors contributed equally to this work
Correspondence to: M. Fontés, INSERM U491, Medical Genetics and Development, Faculté de Médecine de la Timone, 27 Boulevard J. Moulin, 13385 Marseille cedex 5, France E-mail: fontes{at}medecine.univ-mrs.fr
Charcot–Marie–Tooth (CMT) disease is the most frequent hereditary peripheral neuropathy in humans. Its prevalence is about one in 2500. A subform, CMT1A, is transmitted as an autosomal dominant trait. An estimated 75% of patients are affected. This disorder has been shown to be associated with the duplication of a 1.5 Mb region of the short arm of chromosome 17, in which the PMP22 gene has been mapped. We have constructed a murine model of CMT1A by inserting into the murine genome a human YAC containing peripheral myelin protein 22 (PMP22) and its flanking controlling elements. We describe the behaviour of the C22 line (seven copies of YAC, 2.1 times PMP22 overexpression) during the myelination process. Electron microscopy, morphometry, electrophysiology, nerve conduction and expression of specific markers (e.g. Krox20) in normal and pathological Schwann cells demonstrated that PMP22 overexpression leads to a defect in the myelination of axons. The largest axons are the most affected. Only a few demyelination/remyelination processes were observed. Moreover, PMP22 overexpression probably enhances collagen synthesis by fibroblasts, before myelination, demonstrating that structures other than Schwann cells are affected by PMP22 overexpression. Classically, CMT1A was thought to be induced by a demyelination process following a phase of normal myelination, yet our data suggest that dysmyelination should be considered as a major factor for the disease.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Verhamme, I. N. van Schaik, J. H. T. M. Koelman, R. J. de Haan, and M. de Visser The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study Brain, November 5, 2009; (2009) awp251v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tanaka, J. Ma, K. F. Tanaka, K. Takao, M. Komada, K. Tanda, A. Suzuki, T. Ishibashi, H. Baba, T. Isa, et al. Mice with Altered Myelin Proteolipid Protein Gene Expression Display Cognitive Deficits Accompanied by Abnormal Neuron-Glia Interactions and Decreased Conduction Velocities J. Neurosci., July 1, 2009; 29(26): 8363 - 8371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Amici, W. A. Dunn Jr, A. J. Murphy, N. C. Adams, N. W. Gale, D. M. Valenzuela, G. D. Yancopoulos, and L. Notterpek Peripheral Myelin Protein 22 Is in Complex with {alpha}6beta4 Integrin, and Its Absence Alters the Schwann Cell Basal Lamina J. Neurosci., January 25, 2006; 26(4): 1179 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pleasure Chaperoning Motor Neurons Arch Neurol, August 1, 2005; 62(8): 1193 - 1193. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pleasure New Treatments for Denervating Diseases J Child Neurol, March 1, 2005; 20(3): 258 - 262. [Abstract] [PDF]
|
|
|
|
|
|
H. Nodera, H. Bostock, S. Kuwabara, T. Sakamoto, K. Asanuma, S. Jia-Ying, K. Ogawara, N. Hattori, M. Hirayama, G. Sobue, et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A Brain, January 1, 2004; 127(1): 203 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Pleasure Genetics of Charcot-Marie-Tooth Disease Arch Neurol, April 1, 2003; 60(4): 481 - 482. [Full Text] [PDF]
|
|